Supriya Lifescience Limited IPO

Supriya Lifescience Limited is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a strong focus on research and development.

As of October 31, 2021, Supriya Lifescience have niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.

Between fiscal 2017 and 2021, the company has consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India.

The company sells their products in the domestic and international markets. From April 1, 2020 until October 31 2021, the products were exported to 1,296 customers including 346 distributors in 86 countries . The company’s business is spread across various geographies including Europe, Latin America, Asia excluding India and North America. For the year ended March 31, 2021, Europe contributed to 17.40%, Latin America’s sales stood at 19.15%, Asia (excluding India) contributed to 29.27% and North America’s revenue from operation came at about 4.76%. India’s revenue from operation stood at 22.53% and 26.43% for the year ended March 31, 2021 and
for the six month period ended September 30, 2021, respectively.

Supriya Lifescience’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc, AT Planejamento E Desenbolvimento De Negocios Ltda, Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma
Ltd.

The company has a modern manufacturing facility located in Parshuram Lote, Maharashtra, which is approximately 250 km from Mumbai, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 547 KL/ day and seven cleanrooms.

In addition, the company has acquired a plot of land, measuring 12,551 sq.mt, near the present manufacturing facility, wherein the company intends to expand its manufacturing infrastructure.